Entertainment Bharat

Reading Time: 2 minutes




EQL Pharma’s Chief Business Development Officer (CBDO), Carl Lindgren, increases his shareholding in the company. On November 14th, Carl Lindgren has bought 10,000 shares in the Company at an average price of SEK 60.00, a transaction totalling SEK 600,000. The trades were made outside the Stock Market and the shares were bought from the major owner Fårö Capital AB, related to Christer Fåhraeus who is Chairman of the board of EQL Pharma. After the purchases, Lindgren owns a total of 60,000 shares and 100,000 warrants in EQL Pharma.

“EQL is an entrepreneurial company in rapid and profitable growth, and I look forward to contributing to the continued positive development of the company in collaboration with the management, colleagues, and external partners,” says Carl Lindgren. “I believe in the company long-term and think it’s important to have ‘skin in the game,’ so it feels very natural to increase my ownership in EQL,” concludes Carl Lindgren.



For more information contact:

Axel Schörling,

CEO & President EQL Pharma AB (publ)
Phone: +46 (0) 76 317 90 60
E-mail: axel.schorling@eqlpharma.com

Web: www.eqlpharma.com

EQL Pharma AB (publ) in short

EQL Pharma AB specializes in developing and selling generics, i.e., drugs that are medically equivalent to original drugs. The company currently has more than 40 niche generics (i.e., generics with limited competition apart from the original drug) launched in the Nordic markets. In addition to these, there is a significant pipeline of additional niche generics for launch in 2024 and beyond. The business is currently focused entirely on prescription drugs, including hospital products, in the Nordics and selected European markets. EQL Pharma AB has its operations in Lund and is listed on Nasdaq Stockholm. EQL Pharma AB carries out extensive development work in collaboration with leading contract manufacturers and major pharmaceutical companies in the EU and Asia, among others.

Source link

Leave a Reply

Your email address will not be published. Required fields are marked *

Related Posts